Evommune, a Palo Alto, CA-based clinical-stage biotechnology company, raised $50M in Series B funding.
The round was led by co-led by new investor Arix Bioscience and current investors EQT Life Sciences and SymBiosis, with participation from new and existing investors including Amplitude Ventures, and Series A leads Pivotal bioVenture Partners and Andera Partners.
The company intends to use the funds to support its three prioritized pipeline programs targeting highly prevalent inflammatory diseases, including EVO101, a novel small molecule inhibitor of the IRAK4. This molecule is being evaluated in a Phase 2a proof-of-concept trial in patients with atopic dermatitis, with data expected later this year. In addition, Evommune is evaluating EVO756, a preclinical molecule designed to target mast cells by selectively modulating MRGPRX2 to treat chronic spontaneous urticaria and interstitial cystitis, and a discovery program targeting autoimmune diseases via PKCθ.
Founded in 2020 and led by Luis Peña, President and CEO, Evommune is a clinical-stage biotechnology company discovering and developing new ways to treat inflammatory diseases. The company is evolving immunology through its dynamic human tissue-based approach to discover, develop and deliver therapies that address symptoms and halt disease progression.
FinSMEs
26/04/2023